Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078

Full Text:

Abstract

Background. So-called rational drug design is suboptimal when it comes to finding effective and safe drug-based treatment for COVID-19. Another approach seems promising: to reprofile the pharmaceuticals registered in the Anatomical, Therapeutic, and Chemical Classifier (ATC).

Material and methods. Chemoreactome screening, a method that simulates the results of inhibiting viral growth in a cell culture, models the effects of pharmaceuticals on the human virome, and estimates the adverse effects of medicines, was used to reprofile about 2700 pharmaceuticals from the ATC. The information technology behind chemoreactome analysis is based on the topological recognition theory advanced by the Institute of Pharmaceutical Informatics, Federal Research Center for Informatics and Control, Russian Academy of Sciences.

Results. Sixty two pharmaceuticals and 20 micronutrients were found to have a pronounced antiviral effect with minimal side effects. Comparison against data of basic research and clinical trials showed 31 out of 62 pharmaceuticals to have been independently confirmed usable in COVID-19 treatment. These inhibit coronaviral proteins and/or function as adaptogenic molecules that improve the functioning of cells exposed to viral stress. Glucosamine sulfate was found to have the best safety profile and minimum effects on the healthy human virome out of all the tested anticoronaviral micronutrients.

Conclusions. Reprofiling of pharmaceuticals registered in the ATC could significantly speed up the search for more effective and safer drugbased COVID-19 treatments. Several micronutrients show promise for long-term coronavirus prevention, especially in the elderly.

About the Authors

I. Yu. Torshin
Institute of Pharmacoinformatics, Federal Research Center “Informatics and Management”, Russian Academy of Sciences; Big Data Storage and Analysis Center, Lomonosov Moscow State University
Russian Federation

Ivan Yu. Torshin – PhD (Phys. Math.), PhD (Chem.), Senior Researcher. Scopus Author ID: 7003300274; WoS ResearcherID: C-7683-2018; RSCI SPIN-code: 1375-1114

4 Vavilov Str., Moscow 2119333, Russia
1 Leninskie Gory, Moscow 119991, Russia



O. A. Gromova
Institute of Pharmacoinformatics, Federal Research Center “Informatics and Management”, Russian Academy of Sciences; Big Data Storage and Analysis Center, Lomonosov Moscow State University
Russian Federation

Olga A. Gromova – Dr. Med. Sc., Professor, Research Supervisor; Leading Researcher. Scopus Author ID: 7003589812; WoS ResearcherID: J-4946-2017; RSCI SPIN-code: 6317-9833

4 Vavilov Str., Moscow 2119333, Russia
1 Leninskie Gory, Moscow 119991, Russia



A. G. Chuchalin
Pirogov Russian National Research Medical University
Russian Federation

Aleksandr G. Chuchalin – Dr. Med. Sc., Professor, Academician of the Russian Academy of Sciences, Pulmonologist, Head of Chair of Hospital Therapy, Faculty of Pediatrics. RSCI SPIN-code: 7742-2054

16 Pervaya Leonov Str., Moscow 129226, Russia



Yu. I. Zhuravlev
Institute of Pharmacoinformatics, Federal Research Center “Informatics and Management”, Russian Academy of Sciences
Russian Federation

Yuriy I. Zhuravlev – Dr. Math. Sc, Professor, Academician of RAS, Senior Researcher. Scopus Author ID: 7005285135

4 Vavilov Str., Moscow 2119333, Russia



References

1. Torshin I.Yu., Gromova О.А. Micronutrients against coronaviruses. Мoscow: GEOTAR-Media; 2020 (in Russ.).

2. Riva L., Yuan S., Yin X., et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020; 586 (7827): 113–9. https://doi.org/10.1038/s41586-020-2577-1.

3. Shenderov B.А. Medical microbial ecology and functional nutrition. Vol. 3. Probiotics and functional nutrition. Мoscow: GRANT; 2001 (in Russ.).

4. Scarpellini E., Fagoonee S., Rinninella E., et al. Gut microbiota and liver interaction through immune system cross-talk: a comprehensive review at the time of the SARS-CoV-2 pandemic. J Clin Med. 2020; 9 (8): 2488. https://doi.org/10.3390/jcm9082488.

5. Gromova O.A., Torshin I.Yu., Naumov A.V., Maksimov V.A. Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugs. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (3): 270–82 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.049.

6. Kumata R., Ito J., Takahashi K., et al. A tissue level atlas of the healthy human virome. BMC Biol. 2020; 18 (1): 55. https://doi.org/10.1186/s12915-020-00785-5.

7. Xiang J., Wünschmann S., Diekema D.J., et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med. 2001; 345 (10): 707–14. https://doi.org/10.1056/NEJMoa003364.

8. Barton E.S., White D.W., Cathelyn J.S., et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature. 2007; 447 (7142): 326–9. https://doi.org/10.1038/nature05762.

9. Wang L., Candia J., Ma L., et al. Serological responses to human virome define clinical outcomes of italian patients infected with SARSCoV-2.medRxiv. Version 1. medRxiv. Preprint. 2020 Sep 7. https://doi.org/10.1101/2020.09.04.20187088.

10. Torshin I.Yu., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014; 24: 11–23. https://doi.org/10.1134/S1054661814010209.

11. Torshin I.Yu., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs: Part 2. Local completeness of invariants of chemographs in view of the combinatorial theory of solvability. Pattern Recognit Image Anal. 2014; 24: 196–208. https://doi.org/10.1134/S1054661814020151.

12. Bolton E., Wang Y., Thiessen P.A., Bryant S.H. PubChem: Integrated platform of small molecules and biological activities. Chapter 12. Ann Rep Comput Chem. 2008; 4: 217–41. https://doi.org/10.1016/S1574-1400(08)00012-1.

13. Wishart D.S., Tzur D., Knox C., et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007; 35 (Database issue): D521–6. https://doi.org/10.1093/nar/gkl923.

14. Mering C., Jensen L., Snel B., et al. STRING: known and predicted protein–protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005; 33 (Database issue): D433–7. https://doi.org/10.1093/nar/gki005.

15. Torshin I.Yu, Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175.

16. Kuhn M., Letunic I., Jensen L.J., Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016; 44 (D1): D1075–9. https://doi.org/10.1093/nar/gkv1075.

17. Balakrishnan V., Lakshminarayanan K. Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease. Int J Pept Res Thers. 2020; Sep 28: 1–8. https://doi.org/10.1007/s10989-020-10115-6.

18. Kneller D.W., Galanie S., Phillips G., et al. Malleability of the SARSCoV- 2 3CL Mpro active-site cavity facilitates binding of clinical antivirals. Structure. 2020; 28 (12): 1313–20e3. https://doi.org/10.1016/j.str.2020.10.007.

19. Bollo L., Guerra T., Bavaro D.F., et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J Neurol Sci. 2020; 416: 117011. https://doi.org/10.1016/j.jns.2020.117011.

20. Mallucci G., Zito A., Fabbro B.D., Bergamaschi R. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord. 2020; 45: 102414. https://doi.org/10.1016/j.msard.2020.102414.

21. Gomez-Mayordomo V., Montero-Escribano P., Matías-Guiu J.A., et al. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. J Med Virol. 2021: 93 (1): 546–9. https://doi.org/10.1002/jmv.26279.

22. Ciardi M.R., Zingaropoli M.A., Pasculli P., et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. J Neuroimmunol. 2020; 346: 577323. https://doi.org/10.1016/j.jneuroim.2020.577323.

23. Ortega J.T., Serrano M.L., Jastrzebska B. Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis. Biomolecules. 2020; 10 (6): 954. https://doi.org/10.3390/biom10060954.

24. Hogan Ii RB, Hogan Iii RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine – famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020; 63: 101942. https://doi.org/10.1016/j.pupt.2020.101942.

25. Freedberg D.E., Conigliaro J., Wang T.C., et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020; 159 (3): 1129–31.e3. https://doi.org/10.1053/j.gastro.2020.05.053.

26. Patel M., Dominguez E., Sacher D., et al. Etoposide as salvage therapy for cytokine storm due to coronavirus disease 2019. Chest. 2021; 159 (1): e7–11. https://doi.org/10.1016/j.chest.2020.09.077.

27. Takami A. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19. Int J Hematol. 2020; 112 (1): 122–4. https://doi.org/10.1007/s12185-020-02888-9.

28. Smetana K. Jr., Rosel D., BrÁbek J. Raloxifene and Bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality. In Vivo. 2020; 34 (5): 3027–8. https://doi.org/10.21873/invivo.12135.

29. Olagnier D., Farahani E., Thyrsted J., et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and antiinflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020; 11 (1): 4938. https://doi.org/10.1038/s41467-020-18764-3.

30. Fatima S.A., Asif M., Khan K.A., et al. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. Ann Med Surg (Lond). 2020; 60: 413–6. https://doi.org/10.1016/j.amsu.2020.11.027.

31. Rana M.A., Hashmi M., Qayyum A., et al. Comparison of efficacy of dexamethasone and methylprednisolone in improving PaO2/FiO2 ratio among COVID-19 patients. Cureus. 2020; 12 (10): e10918. https://doi.org/10.7759/cureus.10918.

32. Badawy A.A. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep. 2020; 40 (10): BSR20202856. https://doi.org/10.1042/BSR20202856.

33. Kim J., Ochoa M.T., Krutzik S.R., et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002; 169 (3): 1535–41. https://doi.org/10.4049/jimmunol.169.3.1535.

34. Ten Hove A.S., Brinkman D.J., Li Yim A.Y., et al. The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia. Bioelectron Med. 2020; 6: 20. https://doi.org/10.1186/s42234-020-00057-1.

35. Oliveira A.S., Ibarra A.A., Bermudez I., et al. Simulations support the interaction of the SARS-CoV-2 spike protein with nicotinic acetylcholine receptors. Version 3. bioRxiv. Preprint. NaN NaN [revised 2020 Sep 14]. https://doi.org/10.1101/2020.07.16.206680.

36. Blasco H., Bessy C., Plantier L., et al. The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci Rep. 2020; 10 (1): 16824. https://doi.org/10.1038/s41598-020-73966-5.

37. Farsalinos K., Eliopoulos E., Leonidas D.D., et al. Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications. Int J Mol Sci. 2020; 21 (16): 5807. https://doi.org/10.3390/ijms21165807.

38. Ghiasvand F., Ghadimi M., Sadr S., et al. COVID-19 treatment success after repeat courses of azithromycin: a report of three cases. Infect Disord Drug Targets. 2020; Nov 26. https://doi.org/10.2174/1871526520999201126203510.

39. Du X., Zuo X., Meng F., et al. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. Cell Prolif. 2021; 54 (1): e12953. https://doi.org/10.1111/cpr.12953.

40. Renteria A.E., Mfuna Endam L., Adam D., et al. Azithromycin downregulates gene expression of IL-1β and pathways involving TMPRSS2 and TMPRSS11D required by SARS-CoV-2. Am J Respir Cell Mol Biol. 2020; 63 (5): 707–9. https://doi.org/10.1165/rcmb.2020-0285LE.

41. Ulrich H., Pillat M.M. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020; 16 (3): 434–40. https://doi.org/10.1007/s12015-020-09976-7.

42. Scherrmann J.M. Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy. Clin Pharmacol Ther. 2020; 108: 201–11. https://doi.org/10.1002/cpt.2020.

43. Maggio R., Corsini G.U. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020; 157: 104837. https://doi.org/10.1016/j.phrs.2020.104837.

44. Ansarin K., Tolouian R., Ardalan M., et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial. Bioimpacts. 2020; 10 (4): 209–15. https://doi.org/10.34172/bi.2020.27.

45. Bradfute S.B., Ye C., Clarke E.C., et al. Ambroxol and ciprofloxacin show activity against SARS-CoV2 in Vero E6 cells at clinically-relevant concentrations. Version 1. bioRxiv. Preprint. 2020 Aug 11. https://doi.org/10.1101/2020.08.11.245100.

46. Olaleye O.A., Kaur M., Onyenaka C.C. Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein's receptor binding domain and recombinant human ACE2. bioRxiv. Preprint. 2020 Sep 14:2020.09.13.295691. https://doi.org/10.1101/2020.09.13.295691.

47. Kumar P. Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS intervention: what are we waiting for? Front Bioeng Biotechnol. 2020; 8: 577172. https://doi.org/10.3389/fbioe.2020.577172.

48. Brenner S.R. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol. 2020; 92 (1): 2341–2. https://doi.org/10.1002/jmv.26030.

49. Jiménez-Jiménez F.J., Alonso-Navarro H., García-Martín E., Agúndez J.A. Anti-inflammatory effects of amantadine and memantine: possible therapeutics for the treatment of COVID-19? J Pers Med. 2020; 10 (4): 217. https://doi.org/10.3390/jpm10040217.

50. Aranda-Abreu G.E., Aranda-Martínez J.D., Araújo R., et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep. 2020; 72 (6): 1538–41. https://doi.org/10.1007/s43440-020-00168-1.

51. Singh Tomar P.P., Arkin I.T. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochem Biophys Res Commun. 2020; 530 (1): 10–4. https://doi.org/10.1016/j.bbrc.2020.05.206.

52. Hasanagic S., Serdarevic F. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond. Eur Respir J. 2020; 56 (2): 2001610. https://doi.org/10.1183/13993003.01610-2020.

53. Risner K.H., Tieu K.V., Wang Y., et al. Maraviroc inhibits SARS- CoV-2 multiplication and s-protein mediated cell fusion in cell culture. bioRxiv. Preprint. 2020 Aug 13:2020.08.12.246389. https://doi.org/10.1101/2020.08.12.246389.

54. Shamsi A., Mohammad T., Anwar S., et al. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 2020; 40 (6): BSR20201256. https://doi.org/10.1042/BSR20201256.

55. Tariq A., Mateen R.M., Afzal M.S., Saleem M. Paromomycin: a potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. Int J Infect Dis. 2020; 98: 166–75. https://doi.org/10.1016/j.ijid.2020.06.063.

56. Bolelli K., Ertan-Bolelli T., Unsalan O., Altunayar-Unsalan C. Fenoterol and dobutamine as COVID-19 main protease inhibitors: a virtual screening study. J Mol Struct. 2021; 1228: 129449. https://doi.org/10.1016/j.molstruc.2020.129449.

57. Bagheri M., Niavarani A. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike proteinhACE2 binding. J Biomol Struct Dyn. 2020; Oct 8: 1–10. https://doi.org/10.1080/07391102.2020.1830854.

58. Scalise M, Indiveri C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. SLAS Discov. 2020; 25 (10): 1171–3. https://doi.org/10.1177/2472555220934421.

59. Peng H., Chen Z., Wang Y., et al. Systematic review and pharmacological considerations for chloroquine and its analogs in the treatment for COVID-19. Front Pharmacol. 2020; 11: 554172. https://doi.org/10.3389/fphar.2020.554172.

60. Li G., Yuan M., Li H., et al. Safety and efficacy of artemisininpiperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int J Antimicrob Agents. 2021; 57 (1): 106216. https://doi.org/10.1016/j.ijantimicag.2020.106216.

61. Fragoso-Saavedra S., Iruegas-Nunez D.A., Quintero-Villegas A., et al. A parallel-group, multicenter randomized, double-blinded, placebocontrolled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the pyridostigmine in severe COVID-19 (PISCO) trial protocol. BMC Infect Dis. 2020; 20 (1): 765. https://doi.org/10.1186/s12879-020-05485-7.

62. Aliter K.F., Al-Horani R.A. Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19. Cardiovasc Drugs Ther. 2021; 35: 195–203. https://doi.org/10.1007/s10557-020-07066-x.

63. Habibzadeh P., Mofatteh M., Ghavami S., Roozbeh J. The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: a hypothesis. Eur J Pharmacol. 2020; 888: 173487. https://doi.org/10.1016/j.ejphar.2020.173487.

64. Unal G., Turan B., Balcioglu Y.H. Immunopharmacological management of COVID-19: potential therapeutic role of valproic acid. Med Hypotheses. 2020; 143: 109891. https://doi.org/10.1016/j.mehy.2020.109891.

65. Revannasiddaiah S., Kumar Devadas S., Palassery R., et al. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Med Hypotheses. 2020; 144: 109850. https://doi.org/10.1016/j.mehy.2020.109850.

66. Cure E., Cumhur Cure M. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020; 14 (4): 405–6. https://doi.org/10.1016/j.dsx.2020.04.024.

67. Lee D.Y., Lin T.E., Lee C.I., et al. MicroRNA-10a is crucial for endothelial response to different flow patterns via interaction of retinoid acid receptors and histone deacetylases. Proc Natl Acad Sci USA. 2017; 114 (8): 2072–7. https://doi.org/10.1073/pnas.1621425114.

68. Uzzan M., Soudan D., Peoc'h K., et al. Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms. Dig Liver Dis. 2020; 52 (10): 1104–5. https://doi.org/10.1016/j.dld.2020.06.042.

69. Torshin I.Yu., Gromova O.A., Fedotova L.E., et al. Chemoreactomic analysis of citrulline malate molecules. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (2): 30–5 (in Russ.). https://doi.org/10.14412/2074-2711-2017-2-30-35.

70. Legendre F., Bauge C., Roche R., et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1betastimulated chondrocytes-study in hypoxic alginate bead cultures. Osteoarthritis Cartilage. 2008; 16: 105–14. https://doi.org/10.1016/j.joca.2007.05.020.

71. Campo G., Avenoso A., Campo S., et al. Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. Arch Biochem Biophys. 2009; 491: 7–15. https://doi.org/10.1016/j.abb.2009.09.017.

72. Kwon P.S., Oh H., Kwon SJ., et al. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 2020; 6: 50. https://doi.org/10.1038/s41421-020-00192-8.

73. Ferreira A.O., Polonini H.C., Dijkers E.C. Postulated adjuvant therapeutic strategies for COVID-19. J Pers Med. 2020; 10 (3): 80. https://doi.org/10.3390/jpm10030080.

74. DiNicolantonio J., Barroso-Aranda J., McCarty M. Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion. Immunology Letters. 2020; 228: 83–5. https://doi.org/10.1016/j.imlet.2020.09.008.

75. Gromova O.A., Torshin I.Yu., Fedotova L.E. Geriatric information analysis of the molecular properties of mexidole. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (4): 46–54 (in Russ.). https://doi.org/10.14412/2074-2711-2017-4-46-54.

76. Torshin I.Yu., Lila A.М., Limanova O.A., Gromova O.A. Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (1): 23–34 (in Russ.). https://doi.org/10.17749/2070-4909.2020.13.1.23-34.


For citation:


Torshin I.Yu., Gromova O.A., Chuchalin A.G., Zhuravlev Yu.I. Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2021;14(2):191–211. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078

Views: 187


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)